Pozytywny efekt leczenia metabolicznego pacjenta z dławicą piersiową po ostrym zespole wieńcowym Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2012
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Ostrzycki, A. (2012). Pozytywny efekt leczenia metabolicznego pacjenta z dławicą piersiową po ostrym zespole wieńcowym. Medycyna Faktów , 5(1(14), 66-70. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2495
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Guidelines on the management of stable angina pectoris: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27: 1341-1381.
2. ACC/AHA/ACP-ASIM. Guidelines for the management of patients with chronic stable angina. J. Am. Coll. Cardiol. 1999; 33: 2092-2197.
3. Lee L.: Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur. Heart J. 2004; 25: 634-641.
4. Kantor P.F.: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2000; 17(86): 580-588.
5. Sellier P.: Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am. J. Cardiovasc. Drugs 2003; 3: 361-369.
6. Levy S.: Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators. Am. J. Cardiol. 1995; 76: 12B-16B.
7. Detry J.M.: Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br. J. Clin. Pharmacol. 1994; 37: 279-288.
8. Michaelides A.P., Spiropoulos K., Dimopoulos K., Athanasiades D., Toutozas P.: Antianginal Efficacy of the Combination of Trimetazidine-Propranolol Compared with Isosorbide Dinitrate-Propranolol in Patients with Stable Angina. Clin. Drug Invest. 1997; 13(1).
9. Szwed H.: Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur. Heart J. 2001; 22: 2267-2274.
10. Iyengar S.S., Rosano G.M.C.: Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infraction: a preliminary study (METRO). Am. J. Cardiovasc. Drugs 2009; 9(5): 293-297.
11. Gao D., Ning N., Niu X., Hao G., Meng Z.: Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011; 97(4): 278-286.
12. Brottier L., Barat J.L., Combe C., Boussens B., Bonnet J., Bricaud H.: Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur. Heart J. 1990; 11: 207-212.
2. ACC/AHA/ACP-ASIM. Guidelines for the management of patients with chronic stable angina. J. Am. Coll. Cardiol. 1999; 33: 2092-2197.
3. Lee L.: Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur. Heart J. 2004; 25: 634-641.
4. Kantor P.F.: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2000; 17(86): 580-588.
5. Sellier P.: Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am. J. Cardiovasc. Drugs 2003; 3: 361-369.
6. Levy S.: Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators. Am. J. Cardiol. 1995; 76: 12B-16B.
7. Detry J.M.: Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br. J. Clin. Pharmacol. 1994; 37: 279-288.
8. Michaelides A.P., Spiropoulos K., Dimopoulos K., Athanasiades D., Toutozas P.: Antianginal Efficacy of the Combination of Trimetazidine-Propranolol Compared with Isosorbide Dinitrate-Propranolol in Patients with Stable Angina. Clin. Drug Invest. 1997; 13(1).
9. Szwed H.: Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur. Heart J. 2001; 22: 2267-2274.
10. Iyengar S.S., Rosano G.M.C.: Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infraction: a preliminary study (METRO). Am. J. Cardiovasc. Drugs 2009; 9(5): 293-297.
11. Gao D., Ning N., Niu X., Hao G., Meng Z.: Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011; 97(4): 278-286.
12. Brottier L., Barat J.L., Combe C., Boussens B., Bonnet J., Bricaud H.: Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur. Heart J. 1990; 11: 207-212.